AbbVie Inc. (NYSE:ABBV) is one of the best medical stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on AbbVie Inc. (NYSE:ABBV) without assigning a price target.
AbbVie Inc. reported in its fiscal Q2 2025 earnings that the diluted EPS for the quarter reached $0.52 on a GAAP basis, reflecting a 32.5% drop.
Adjusted diluted EPS, however, rose 12.1% to $2.97. Management reported that the results included an “unfavorable impact of $0.42 per share related to acquired IPR&D and milestones expense”.
Furthermore, net revenue for fiscal Q2 2025 rose 6.6% on a reported basis to $15.423 billion.
AbbVie Inc. is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
